Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial

Archives of Dermatological Research

Volumn 307, Issue 4, 2015, Pages 299-307

  El Darouti, Mohammad A ^a   Hegazy, Rehab A ^a   Abdel Hay, Rania M ^a   El Hawary, Marwa S ^a   Tawdy, Amira M ^a   Fawzy, Marwa M ^a   Rashed, Laila A ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Acantholysis; Blistering disease; Interferon gamma; Interleukin 4

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; RECOMBINANT PROTEIN; SALAZOSULFAPYRIDINE;

ADULT; BLOOD; CONTROLLED STUDY; DRUG COMBINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PEMPHIGUS; RANDOMIZED CONTROLLED TRIAL; TH1 CELL; TH2 CELL;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-4; MALE; MIDDLE AGED; PEMPHIGUS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RECOMBINANT PROTEINS; SULFASALAZINE; TH1 CELLS; TH2 CELLS;

EID: 84939949333     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-014-1522-2     Document Type: Article

References (26)

1. Afshar M, Martinez AD, Gallo RL, Hata TR (2013) Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol 27:771–778
2. Agarwal M, Walia R, Kochhar AM, Chander R (1998) Pemphigus Area and Activity Score (PAAS)—a novel clinical scoring method for monitoring of pemphigus vulgaris patients. Int J Dermatol 37:158–160
3. Alecu M, Alecu S, Coman G, Gălăţescu E, Ursaciuc C (1999) ICAM-1, ELAM-1, TNF-alpha and IL-6 in serum and blister liquid of pemphigus vulgaris patients. Roum Arch Microbiol Immunol 58(2):121–130
4. Asmuth DM, Abel K, George MD, Dandekar S, Pollard RB, Miller CJ (2008) Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques. J Med Primatol 37:26–30
5. Berger A (2000) Th1 and Th2 responses: what are they? BMJ 321:424
6. Bernard P, Aucouturier P, Denis F, Bonnetblanc JM (1990) Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopathol 54:489–494
7. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR (1995) Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci USA 92:5239–5243
8. Caproni M, Giomi B, Cardinali C, Salvatore E, Pestelli E, D’Agata A, Bianchi B et al (2001) Further support for a role for Th2-like cytokines in blister formation of pemphigus. Clin Immunol 98:264–271
9. Christophoridis S, Büdinger L, Borradori L, Hunziker T, Merk HF, Hertl M (2000) IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous disease. Br J Dermatol 143:349–355
10. D’Auria L, Bonifati C, Mussi A, D’Agosto G, De Simone C, Giacalone B et al (1997) Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 8:383–387
11. El-Darouti M, Marzouk S, Abdel Hay R, el-Tawdy A, Fawzy M, Leheta T et al (2009) The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. Br J Dermatol 161:313–319
12. Eming R, Büdinger L, Riechers R, Christensen O, Bohlen H, Kalish R et al (2000) Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay. Br J Dermatol 143:1279–1282
13. Fleischmann M, Celerier P, Bernard P, Litoux P, Dreno B (1996) Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology 192:50–55
14. Hertl M, Eming R, Veldman C (2006) T cell control in autoimmune bullous skin disorders. J Clin Invest 116:1159–1166
15. Kirsner RS, Anhalt GJ, Kerdel FA (1995) Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol 132:474–478
16. Lin MS, Swartz SJ, Lopez A, Fernandez-Vina MA, Stastny P, Fairley JA et al (1997) Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 99:31–40
17. Markine-Goriaynoff D, Coutelier J-P (2002) Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J Virol 76:432–435
18. Nagao Y, Kawaguchi T, Ide T, Kumashiro R, Sata M (2005) Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C. Int J Mol Med 15:237–241
19. Nagel A, Lang A, Engel D, Podstawa E, Hunzelmann N, de Pita O et al (2010) Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 134:320–330
20. Niizeki H, Inamoto N, Nakamura K, Tsuchimoto K, Hashimoto T, Nishikawa T (1994) A case of pemphigus foliaceus after interferon alpha-2a therapy. Dermatology 189(Suppl 1):129–130
21. Parodi A, Semino M, Gallo R, Rebora A (1993) Bullous eruption with circulating pemphigus-like antibodies following interferon-alpha therapy. Dermatology 186:155–157
22. Rahbar Z, Daneshpazhooh M, Mirshams-Shahshahani M, Esmaili N, Heidari K, Aghazadeh N et al (2014) Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score. JAMA Dermatol 150:266–272
23. Rico-Rosillo MG, Vega-Robledo GB (2012) Immunological mechanisms involved in pregnancy. Ginecol Obstet Mex 80:332–340
24. Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M (2003) Dichotomy of autoreactive Th1 and TH2 responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol 170:635–642
25. Vial T, Descotes J (1994) Clinical toxicity of the interferons. Drug Saf 10:115–150
26. Yokoyama T, Amagai M (2010) Immune dysregulation of pemphigus in humans and mice. J Dermatol 37:205–213